ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
The research was supported by the BGU Coronavirus Challenge and the Israeli Ministry of Health.
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
Subscribe To Our Newsletter & Stay Updated
